News | July 22, 2025
AstraZeneca plans to invest $50 billion in US by 2030
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
Capricor’s BLA for Deramiocel received Priority Review in March 2025
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013
Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture
Approval is based on positive data from the Phase 3 ECHELON-3 trial
New Jersey-based manufacturing site to support innovative decentralized approach for improved patient experience
Subscribe To Our Newsletter & Stay Updated
